ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients
September 27, 2020Rigel Pharmaceuticals announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. -
Rigel Announces Trial of Fostamatinib for COVID-19 Pneumonia
July 22, 2020Rigel Pharmaceuticals announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of COVID-19 ...
Pharma Sources Insight January 2025
